Quarterly report pursuant to Section 13 or 15(d)

FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)

v3.24.3
FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS

As of December 31, 2023, we had contingent consideration that is required to be measured at fair value on a recurring basis.

 

Our financial instruments measured at fair value on a recurring basis were as follows at the dates indicated:

 

(in thousands)       Level 1     Level 2     Level 3     Total  
    Condensed Consolidated
Balance Sheet Caption		   Fair Value at
December 31, 2023		  
(in thousands)       Level 1     Level 2     Level 3     Total  
Liabilities:                                    
Contingent consideration - current   Accrued expenses and other current liabilities   $ —     $ —       1,500       1,500  
Total Liabilities       $ —     $ —     $ 1,500     $ 1,500  
SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION

A reconciliation of our liabilities that are measured and recorded at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows:

 

(in thousands)   Nine Months Ended
September 30, 2024		  
Balance at December 31, 2023   $ 1,000  
Cash payments for earned contingent consideration     —  
Transfer to notes payable     —  
Gain from fair value adjustments included in results of operations     (1,000 )
Balance September 30, 2024   $ —  

 

(in thousands)   Nine Months Ended
September 30, 2023		  
Balance at December 31, 2022   $ 2,738  
Cash payments for earned contingent consideration     (350 )
Transfer to notes payable     (1,150 )
Loss (gain) from fair value adjustments included in results of operations     262  
Balance at September 30, 2023   $ 1,500